Danaher Corporation (DHR)vsMerck & Company Inc (MRK)
DHR
Danaher Corporation
$204.76
+2.39%
HEALTHCARE · Cap: $125.93B
MRK
Merck & Company Inc
$128.58
+0.16%
HEALTHCARE · Cap: $316.14B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 162% more annual revenue ($65.77B vs $25.11B). DHR leads profitability with a 16.0% profit margin vs 13.6%. DHR appears more attractively valued with a PEG of 1.15. DHR earns a higher WallStSmart Score of 66/100 (B-).
DHR
Strong Buy66
out of 100
Grade: B-
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-66.7%
Fair Value
$117.88
Current Price
$204.76
$86.88 premium
Margin of Safety
-58.0%
Fair Value
$81.23
Current Price
$128.58
$47.35 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 59.7% YoY
Large-cap with strong market position
Reasonable price relative to book value
Generating 1.3B in free cash flow
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
ROE of 7.6% — below average capital efficiency
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : DHR
The strongest argument for DHR centers on EPS Growth, Market Cap, Price/Book. Profitability is solid with margins at 16.0% and operating margin at 18.0%. PEG of 1.15 suggests the stock is reasonably priced for its growth.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio, Return on Equity.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
DHR profiles as a mature stock while MRK is a value play — different risk/reward profiles.
DHR carries more volatility with a beta of 0.82 — expect wider price swings.
DHR is growing revenue faster at 5.5% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
DHR scores higher overall (66/100 vs 50/100), backed by strong 16.0% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?